| Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo JA Morales-Garcia, R Luna-Medina, S Alonso-Gil, M Sanz-SanCristobal, ... ACS chemical neuroscience 3 (11), 963-971, 2012 | 165 | 2012 |
| Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice AV Franklin, MK King, V Palomo, A Martinez, LL McMahon, RS Jope Biological psychiatry 75 (3), 198-206, 2014 | 125 | 2014 |
| Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities V Palomo, I Soteras, DI Perez, C Pérez, C Gil, NE Campillo, A Martinez Journal of medicinal chemistry, 2011 | 120 | 2011 |
| Photoligation of an amphiphilic polymer with mixed coordination provides compact and reactive quantum dots W Wang, A Kapur, X Ji, M Safi, G Palui, V Palomo, PE Dawson, ... Journal of the American Chemical Society 137 (16), 5438-5451, 2015 | 108 | 2015 |
| 5-Imino-1, 2, 4-Thiadiazoles: First Small Molecules As Substrate Competitive Inhibitors of Glycogen Synthase Kinase 3 V Palomo, DI Perez, C Pérez, JA Morales, I Soteras, S Alonso-Gil, ... Journal of Medicinal Chemistry, 2012 | 99 | 2012 |
| Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3 E Beurel, O Kaidanovich-Beilin, WI Yeh, L Song, V Palomo, SM Michalek, ... The Journal of Immunology 190 (10), 5000-5011, 2013 | 98 | 2013 |
| PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury I Paterniti, E Mazzon, C Gil, D Impellizzeri, V Palomo, M Redondo, ... PloS one 6 (1), e15937, 2011 | 90 | 2011 |
| Purple-, blue-, and green-emitting multishell alloyed quantum dots: synthesis, characterization, and application for ratiometric extracellular pH sensing K Susumu, LD Field, E Oh, M Hunt, JB Delehanty, V Palomo, PE Dawson, ... Chemistry of Materials 29 (17), 7330-7344, 2017 | 86 | 2017 |
| Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds DI Perez, V Palomo, C P rez, C Gil, PD Dans, FJ Luque, S Conde, ... Journal of medicinal chemistry, 2011 | 85 | 2011 |
| Delivery and tracking of quantum dot peptide bioconjugates in an intact developing avian brain R Agarwal, MS Domowicz, NB Schwartz, J Henry, I Medintz, JB Delehanty, ... ACS chemical neuroscience 6 (3), 494-504, 2015 | 81 | 2015 |
| Glycogen Synthase Kinase-3 Inhibitors as Potent Therapeutic Agents for the Treatment of Parkinson Disease. JA Morales-Garcia, C Susin, S Alonso-Gil, DI Perez, V Palomo, C Pérez, ... ACS Chemical Neuroscience, 2013 | 77 | 2013 |
| T cells control the generation of nanomolar-affinity anti-glycan antibodies Z Polonskaya, S Deng, A Sarkar, L Kain, M Comellas-Aragones, ... The Journal of clinical investigation 127 (4), 1491-1504, 2017 | 76 | 2017 |
| Subtly modulating glycogen synthase kinase 3 β: allosteric inhibitor development and their potential for the treatment of chronic diseases V Palomo, DI Perez, C Roca, C Anderson, N Rodríguez-Muela, C Perez, ... Journal of medicinal chemistry 60 (12), 4983-5001, 2017 | 72 | 2017 |
| Dual inhibitor of PDE7 and GSK-3–VP1. 15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice TV Lipina, V Palomo, C Gil, A Martinez, JC Roder Neuropharmacology 64, 205-214, 2013 | 68 | 2013 |
| Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival EM Medina-Rodríguez, FJ Arenzana, J Pastor, M Redondo, V Palomo, ... Cellular and molecular life sciences 70, 3449-3462, 2013 | 60 | 2013 |
| Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015) V Palomo, A Martinez Expert opinion on therapeutic patents 27 (6), 657-666, 2017 | 58 | 2017 |
| UV and sunlight driven photoligation of quantum dots: understanding the photochemical transformation of the ligands F Aldeek, D Hawkins, V Palomo, M Safi, G Palui, PE Dawson, I Alabugin, ... Journal of the American Chemical Society 137 (7), 2704-2714, 2015 | 58 | 2015 |
| TDP-43: a key therapeutic target beyond amyotrophic lateral sclerosis V Palomo, C Tosat-Bitrian, V Nozal, S Nagaraj, A Martin-Requero, ... ACS chemical neuroscience 10 (3), 1183-1196, 2019 | 57 | 2019 |
| Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis EM Medina-Rodríguez, A Bribián, A Boyd, V Palomo, J Pastor, A Lagares, ... Scientific Reports 7 (1), 43545, 2017 | 53 | 2017 |
| 5-Imino-1, 2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3β (GSK-3β) and phosphodiesterase 7 (PDE7) inhibitors: Determination of blood–brain barrier … DI Pérez, M Pistolozzi, V Palomo, M Redondo, C Fortugno, C Gil, G Felix, ... European Journal of Pharmaceutical Sciences, 2012 | 49 | 2012 |
